NaimAlkhouriMD

PubMed

• THE TRENDS AND INCIDENCE OF ALCOHOL-ASSOCIATED HEPATITIS HOSPITALIZATIONS FROM 2016-2020 AND THE IMPACT OF THE COVID-19 PANDEMIC.
  Wijarnpreecha, K., Megan B Ghai, Pooja Rangan, Naim Alkhouri, Jessica Mellinger, Karn Wijarnpreecha> ;Alcohol. 2024 Mar 7
• Letter: Severe underweight and sarcopenia in decompensated cirrhosis are associated with high FGF21 levels-authors' reply.
  Tseng, L., Balic, K., Mansbach, H., Margalit, M., Alkhouri, N.> ;Alimentary Pharmacology & Therapeutics. 2024 Mar 1
• 11 citations
  Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.
  Loomba, R., Zobair M Younossi, Saleh A Alqahtani, Khalid Alswat, Yusuf Yilmaz, Caglayan Keklikkiran, Jesús Funuyet-Salas, Manuel Romero-Gómez, Jian-Gao Fan, Ming-Hua Z...> ;Journal of Hepatology. 2024 Mar 1
• Degree of Discordance Between FIB-4 and Transient Elastography: An Application of Current Guidelines on General Population Cohort.
  Madeleine Chang, Devon Chang, Sudha Kodali, Stephen A Harrison, Mark Ghobrial, Naim Alkhouri, Mazen Noureddin> ;Clinical Gastroenterology and Hepatology. 2024 Feb 29
• Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction-associated steatohepatitis.
  Francque, S., Hodge, A., Boursier, J., Rodriguez-Araujo, G., Park, G., Younes, Z., Alkhouri, N., Abdelmalek, M.> ;Hepatology Communications. 2024 Feb 1
• Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH.
  Naim Alkhouri, Carl LaCerte, Jeffrey Edwards, Fred Poordad, Eric Lawitz, Lois Lee, Sharon Karan, Sangeeta Sawhney, Mary Erickson, Leigh MacConell, Luna Zaru, Jianfen C...> ;Liver International. 2024 Apr 1
• Missed Opportunities in Guideline-based Fatty Liver Screening among 3.5 million children.
  Reema Gulati, Kabir Gulati, Naim Alkhouri, Herman Sahni, Maroun J Mhanna, David C Kaelber, Hafiza Mehreen Durrani, Roamaa Suri> ;Academic Pediatrics. 2024 Jan 24
• Letter to the Editor: Comparing quantitative MRI technologies in steatotic liver disease.
  Naim Alkhouri, Mukesh Harisinghani> ;Hepatology. 2024 Apr 1
• 21 citations
  Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.
  Stephen A Harrison, Rebecca Taub, Guy W Neff, K Jean Lucas, Dominic Labriola, Sam E Moussa, Naim Alkhouri, Mustafa R Bashir> ;Nature Medicine. 2023 Nov 1
• A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis.
  Mary E Rinella, Hsiao D Lieu, Kris V Kowdley, Zachary D Goodman, Naim Alkhouri, Eric Lawitz, Vlad Ratziu, Manal F Abdelmalek, Vincent Wai-Sun Wong, Ziad H Younes, Aasi...> ;Hepatology. 2024 Mar 1
• 2 citations
  Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis.
  Naim Alkhouri, Donald Lazas, Rohit Loomba, Juan P Frias, Shibao Feng, Leo Tseng, Kemal Balic, Germaine D Agollah, Tinna Kwan, Janani S Iyer, Linda Morrow, Hank Mansbac...> ;Alimentary Pharmacology & Therapeutics. 2023 Nov 1
• 5 citations
  A global action agenda for turning the tide on fatty liver disease.
  Jeffrey V Lazarus, Henry E Mark, Alina M Allen, Juan Pablo Arab, Patrizia Carrieri, Mazen Noureddin, William Alazawi, Naim Alkhouri, Saleh A Alqahtani, Quentin M Anste...> ;Hepatology. 2024 Feb 1
• 18 citations
  A global research priority agenda to advance public health responses to fatty liver disease.
  Jeffrey V Lazarus, Henry E Mark, Alina M Allen, Juan Pablo Arab, Patrizia Carrieri, Mazen Noureddin, William Alazawi, Naim Alkhouri, Saleh A Alqahtani, Marco Arrese, R...> ;Journal of Hepatology. 2023 Sep 1
• 3 citations
  Wilson disease: a summary of the updated AASLD Practice Guidance.
  Naim Alkhouri, Regino P Gonzalez-Peralta, Valentina Medici> ;Hepatology Communications. 2023 Jun 1
• Can Nonalcoholic Steatohepatitis Be Surgically Cured?: Liver Histologic Comparison After Metabolic Surgery Versus Usual Care.
  Ali Aminian, Rickesha Wilson, Abbas Al-Kurd, James Bena, Hana Fayazzadeh, Naim Alkhouri, Steven E Nissen, Srinivasan Dasarathy> ;Annals of Surgery. 2024 Feb 1
• 2 citations
  Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+ and 4 scores.
  Mazen Noureddin, Edward Mena, Raj Vuppalanchi, Niharika Samala, Micaela Wong, Fabiana Pacheco, Prido Polanco, Celine Sakkal, Ani Antaramian, Devon Chang, Nabil Nouredd...> ;Hepatology Communications. 2023 May 1
• 3 citations
  Artificial Intelligence Applications in Hepatology.
  Jörn M Schattenberg, Naga Chalasani, Naim Alkhouri> ;Clinical Gastroenterology and Hepatology. 2023 Jul 1
• 21 citations
  Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study.
  Quentin M Anstee, Brent A Neuschwander-Tetri, Vincent Wai-Sun Wong, Manal F Abdelmalek, Gerardo Rodriguez-Araujo, Henrik Landgren, Grace S Park, Pierre Bedossa, Naim A...> ;Clinical Gastroenterology and Hepatology. 2024 Jan 1
• 1 citations
  The association between perceived stress, acculturation, and non-alcoholic fatty liver disease in Mexican-origin adults in Southern Arizona.
  Adriana Maldonado, Edgar A Villavicencio, Rosa M Vogel, Thaddeus W Pace, John M Ruiz, Naim Alkhouri, David O Garcia> ;Preventive Medicine Reports. 2023 Apr 1
• 46 citations
  Challenges and opportunities in NASH drug development.
  Stephen A Harrison, Alina M Allen, Julie Dubourg, Mazen Noureddin, Naim Alkhouri> ;Nature Medicine. 2023 Mar 1
• 8 citations
  The use of current knowledge and non-invasive testing modalities for predicting at-risk non-alcoholic steatohepatitis and assessing fibrosis.
  Marcelo Kugelmas, Mazen Noureddin, Nadege Gunn, Kimberly Brown, Zobair Younossi, Manal Abdelmalek, Naim Alkhouri> ;Liver International. 2023 May 1
• 4 citations
  Elbasvir/grazoprevir in children aged 3-18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study.
  Regino P Gonzalez-Peralta, Stefan Wirth, Robert H Squires, Frauke Mutschler, Thomas Lang, Malgorzata Pawlowska, Wojciech Sluzewski, Ewa Majda-Stanislawska, Bjorn Fisch...> ;Hepatology Communications. 2023 Mar 1
• 8 citations
  MRI-AST (MAST) Score Accurately Predicts Major Adverse Liver Outcome, Hepatocellular Carcinoma, Liver Transplant, and Liver-Related Death.
  Emily Truong, Jeffrey A Gornbein, Ju Dong Yang, Nabil Noureddin, Stephen A Harrison, Naim Alkhouri, Mazen Noureddin> ;Clinical Gastroenterology and Hepatology. 2023 Sep 1
• 11 citations
  A multistakeholder approach to innovations in NAFLD care.
  Jörn M Schattenberg, Alina M Allen, Helen Jarvis, Shira Zelber-Sagi, Ken Cusi, John F Dillon, Cyrielle Caussy, Sven M Francque, Zobair Younossi, Naim Alkhouri, Jeffrey...> ;Communications Medicine. 2023 Jan 3
• 3 citations
  Prevalence of at-risk NASH and its association with metabolic syndrome in US adults with NAFLD, 2017-2018.
  Julia Y Payne, Naim Alkhouri, Phuc Le, Michael B Rothberg, Prido Polanco, Celine Sakkal, Srinivasan Dasarathy> ;Hepatology Communications. 2023 Jan 1
• Join now to see all

Journal Articles

• NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications for Liver Transplant and Ethnic and Gender Variances  
  Tsuyoshi Todo, Walid S Ayoub, Naim Alkhouri, Nicholas N Nissen, Vinay Sundaram, Shelly C Lu, Mazen Noureddin, Aarshi Vipani, Tram Tran, Andrew S Klein, Nature